Floatz logo

Girentuximab

Cancer of Kidney

Heidelberg Pharma AGmonoclonal_antibodyPhase 3Dormant
BB
69/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
56/ 100
Competitive Position
95/ 100

Competitive context

70 Active assets in the Cancer of Kidney cohort.

Asset / SponsorPhaseRating
Alpha-Interferon
Dartmouth-Hitchcock Medical Center
Phase 3BBB
Girentuximab
Memorial Sloan Kettering Cancer Center
Phase 3BB
ETOPOSIDE
City of Hope Medical Center
Phase 3BB
Ifosfamide
City of Hope Medical Center
Phase 3BB
FLUOROURACILUM
Medical Research Council
Phase 3BB

View all 50 →

Same molecule, other indications

Girentuximab is also rated in:

kidney cancerDormant
BB
Indicative ·
70 / 100
View asset →
nonpapillary renal cell carcinomaDormant
BB
Indicative ·
67 / 100
View asset →
renal cell carcinomaDormant
BB
Indicative ·
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →